Weight Loss Treatments
46 articles on Weight Loss Treatments, researched and written by the Shotlee Editorial Team from primary sources.
Study Links Hormonal Birth Control Use to Higher Likelihood of Needing Weight Loss Injections
A recent Danish study suggests that women who have used hormonal birth control may be more likely to seek weight loss injections such as Wegovy and Ozempic. This research sheds light on a long-reported, yet often unproven, connection between contraceptives and weight changes.
7 min read
AI Helps Stanford Scientists Discover Natural Ozempic Without the Usual Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that may suppress appetite and reduce body weight in a way that resembles semaglutide, the active ingredient in Ozempic.
8 min read
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
The Workforce Runs on Weight Loss Drugs? Employees on GLP-1s Take Fewer Sick Days
A new study reveals significant reductions in long-term sick leave for workers taking GLP-1 medications, offering insights into workplace productivity and long-term health savings.
10 min read
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising Claims in Legal Battle
Novo Nordisk has filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising regarding GLP-1 weight loss medications.
7 min read
Amy Schumer Shows Off Ongoing Weight Loss, Says C-Section Scar Makes Her a 'Warrior'
Comedian Amy Schumer discusses her 50-pound weight loss journey, Cushing syndrome diagnosis, and C-section recovery in a candid new update.
10 min read
Bariatric Surgery Shows 5x More Weight Loss Than GLP-1s in Real-World Study
A groundbreaking real-world comparison study presented at the ASMBS 2025 Annual Scientific Meeting found that bariatric surgery resulted in approximately five times more weight loss compared to popular GLP-1 receptor agonist medications over a two-year period. This research highlights important considerations for patients and healthcare providers navigating weight management options.
7 min read
Novo Nordisk's Semaglutide Implant Could Replace Ozempic Injections
Novo Nordisk and Vivani Medical are developing a semaglutide implant that could eliminate the need for weekly injections. Here is everything to know about the technology.
6 min read
Ozempic's Oral Twin: A Needle-Free Weight Loss Revolution Arrives?
A new era in weight management may be dawning as an oral medication, mirroring the efficacy of popular injectables like Ozempic, is poised for approval. This development promises a more accessible and convenient path to weight loss for millions.
7 min read
Navigating Medicare's New Path for GLP-1 Weight Loss Coverage
For years, Medicare coverage for GLP-1 medications like Ozempic and Wegovy was strictly limited to diabetes management. A significant shift is underway, however, as a new 'Bridge' program opens doors for weight loss coverage, albeit with specific requirements and nuances that patients must navigate.
6 min read
Ozempic Alternative Found: Stanford’s BRP Peptide Breakthrough
A new study reveals BRP, a natural peptide, may offer the benefits of Ozempic without common side effects.
7 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.
7 min read
Alli Weight Loss Pill: FDA Flags Serious Kidney Risks
The Food and Drug Administration (FDA) has issued a new warning regarding potential serious kidney complications associated with Alli, the sole over-the-counter weight loss medication available in the United States. The drug's label has been updated to reflect these risks, urging caution for consumers.
8 min read
Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39
The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.
7 min read
Illicit Weight Loss Drug Ring Dismantled: 12,000 Doses Seized
A major bust at a country estate near Northampton has led to the seizure of 12,000 doses of illicit weight loss medications, including potent peptide drugs. Two men have been arrested as the Medicines and Healthcare products Regulatory Agency (MHRA) cracks down on dangerous counterfeit and unlicensed medicines.
6 min read
Oral GLP-1s Enter the Ring: Early Trends Favoring Foundao Over Wegovy's Pill
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
6 min read
Beyond Ozempic: How MCT Oil Offers Natural Weight & Wellness Support
Discover the natural power of MCT oil, a coconut derivative that's gaining attention for its potential to aid weight loss, boost energy, and enhance mental clarity. Learn how it works and if it's the right choice for you.
9 min read
Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies
Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.
7 min read
Hims & Hers Downgrade: What It Means for GLP-1 Weight Loss Access
Bank of America cuts Hims & Hers price target as the telehealth giant pivots from compounded GLP-1s to branded alternatives. Here is what this shift means for patients.
8 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
Duodenal Resurfacing: A New Hope Beyond GLP-1 Weight Loss?
The emergence of GLP-1 receptor agonists has revolutionized obesity treatment, but concerns about weight regain upon discontinuation are significant. New research on duodenal mucosal resurfacing suggests a potential breakthrough in maintaining weight loss long-term.
7 min read
Amazon Launches GLP-1 Weight Loss Program with Fast Access
Amazon is entering the GLP-1 weight loss market with a new program through One Medical and Amazon Pharmacy, promising fast, convenient access to treatments like Wegovy and Zepbound. With pricing as low as $25/month for insured patients and same-day delivery, it positions weight management as a chronic care solution. This could transform how patients access these popular medications.
5 min read
Novo Nordisk's FDA-Approved GLP-1s Now on Hims & Hers
Hims & Hers Health, Inc. has partnered with Novo Nordisk to bring a broad assortment of FDA-approved GLP-1 medications to eligible customers, including the groundbreaking Wegovy® pill. This collaboration simplifies access with affordable prices, expanded doses, and diverse delivery methods. As the largest global consumer health platform for these approved meds, Hims & Hers is transforming weight management options.
4 min read
Florida Man Charged for Illegally Selling Off-Brand Ozempic
A St. Johns County man, Adam K. Taylor, is now facing federal misdemeanor charges for misbranding and selling off-brand versions of Ozempic (semaglutide) and other GLP-1 drugs without prescriptions. Operating AKT Labs as 'research purposes only,' he instructed undercover officers on weight loss use. This case highlights dangers of unregulated peptides sourced from China.
5 min read
Experts on Hims & Hers' $1.15B Eucalyptus Acquisition
Hims & Hers is acquiring Australian telehealth firm Eucalyptus for $1.15 billion to fuel global growth amid U.S. regulatory scrutiny over compounded GLP-1s. Experts call it a smart diversification move that complements weight loss and wellness services. This expansion could reshape access to personalized care worldwide.
5 min read
Types of Weight Loss Medications: Comparing Key Options
Weight loss medications are gaining attention for treating obesity and overweight, with eight approved types working in unique ways. From GLP-1 receptor agonists mimicking fullness hormones to stimulants like Qsymia reducing appetite, find out which might work best for your goals. This guide compares options, costs, and eligibility criteria to help you choose wisely.
6 min read
Mysterious Flat Affect Symptom in GLP-1 Users
Patients on GLP-1 medications are reporting a puzzling flat affect—not depression, but a sense of 'what's the point?' toward life goals and social plans. One doctor noticed this in three patients within a week, prompting deeper research into GLP-1s' impact on dopamine and motivation. Could this be an emerging side effect?
5 min read
Lilly Stockpiles $1.5B Orforglipron Ahead of FDA Approval Signal
Eli Lilly is sending a clear signal of confidence in its upcoming GLP-1 obesity pill, orforglipron, by stockpiling $1.5 billion worth of inventory ahead of FDA approval. This move, up from $550 million last year, anticipates robust demand without the supply chain issues that plagued injectables like Wegovy from 2022-2024. Here's what it means for patients seeking oral weight loss options.
5 min read
Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
5 min read
HSE's €500k Daily Spend on Ozempic & Saxenda: Key Facts
Ireland's HSE shelled out over €500k daily last year on GLP-1 injections like Ozempic and Saxenda for patients on free schemes. With usage surging 33% since 2023, explore the spending breakdown, regional variations, and what this means for access to these diabetes and weight loss treatments. Understand the science, eligibility, and future of drugs like Mounjaro.
4 min read
GLP-1 Drugs Risk Bone & Muscle Loss in Menopause
GLP-1 receptor agonists drive effective weight loss but can accelerate bone and muscle loss in postmenopausal women. Aging naturally reduces muscle mass and bone density, and rapid weight loss amplifies these risks. Protect your health with resistance exercise, adequate protein, and comprehensive monitoring.
2 min read
AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments
AbbVie is bolstering its obesity portfolio with GUBamy, an amylin-based drug from Gubra as a GLP-1 alternative. Unlike gut hormone-mimicking GLP-1s like Wegovy and Zepbound, amylin targets pancreatic hormones for improved tolerability and muscle retention. The company eyes long-term efficacy amid a $150B market boom.
1 min read
Obesity Medications: How They Might Transform the GLP-1 Sector
The GLP-1 market, initially dominated by weekly injections, is entering a new phase with the introduction of obesity pills. These oral options from Novo Nordisk and Eli Lilly promise greater convenience and possibly lower costs, attracting new users and reshaping the industry. Analysts predict significant market growth, with pills capturing a substantial share by 2030.
9 min read
2026 Signals the Era of Obesity Pills: Uncovering Their Role in Transforming the GLP-1 Market
The year 2026 heralds a shift in obesity treatment with the arrival of GLP-1 pills from Novo Nordisk and Eli Lilly, offering potential alternatives to injections. These oral options promise greater convenience and affordability, possibly attracting new patients to weight loss therapies. Experts highlight their role in expanding the market while maintaining similar efficacy.
2 min read
Nature's Ozempic: Can This OTC Supplement Truly Meet Weight Loss Expectations?
Many people turn to GLP-1 drugs like Ozempic for weight loss, but cost can be a barrier. Affordable alternatives like berberine offer hope, yet experts caution against unrealistic hype. This article examines its benefits, side effects, and potential as a weight loss aid.
3 min read
Pre-GLP-1 Injections: Crucial Exams Physicians Recommend
GLP-1 injectable treatments have surged in popularity in India, prompting medical professionals to emphasize comprehensive diagnostic evaluations before initiating therapy. Key assessments cover metabolic health, organ function, and specific risks to guarantee patient safety. This approach underscores the importance of medical oversight for these potent medications.
5 min read
Key Insights on Weight Loss Medications for 2026
Weight loss medications such as Wegovy and Zepbound are set to become more accessible and affordable, moving beyond high costs and weekly shots. New pill forms offer alternatives for those avoiding injections, with significant developments in GLP-1 treatments expected. Advances in pricing and access programs aim to broaden availability for patients.
6 min read
2026 Set to Deliver Additional GLP-1 Weight Loss Treatments – Alongside Shifting Routines. Specific Investments Ready for Gains
As obstacles to GLP-1 drug adoption diminish in 2026 with lower prices and oral options, usage is expected to surge, reshaping consumer behaviors and creating investment prospects. Market data reveals trends in treatment duration and household impacts, while analysts highlight emerging segments and company adaptations.
5 min read
Let Them Eat Cake: A Solution for Obesity Exists, Yet Only the Affluent Can Access It
Scientific advancements in obesity treatment have revolutionized weight management, but financial barriers ensure these benefits primarily serve the rich. From costly medications to inaccessible surgeries, the struggle reveals deep societal inequalities. Addressing this requires structural changes to make health equitable for all.
5 min read
Weight Loss Innovations Remain Unattainable for Most
Revolutionary advancements in weight loss treatments, including medications like GLP-1 agonists and bariatric surgery, offer promising results but are often unaffordable. High expenses and limited insurance hinder access for many, turning health solutions into privileges. This exacerbates social disparities, demanding structural changes for equitable healthcare.
5 min read
GLP-1 Pill Clearance Drives Food Companies to Protein and Scaled-Down Servings
The recent approval of GLP-1 weight-loss pills by the FDA is influencing food companies to adapt by emphasizing protein and reducing portion sizes. Analysts predict broader adoption of these pills will accelerate changes in consumer eating habits and industry offerings. Companies like Conagra and Nestle are already reformulating products to cater to this growing market.
4 min read
GLP-1 Weight Loss Surge Fueled by Urban Affluent; Distribution and Cost Adjustments Could Alter Trajectory
Urban elites are currently the main drivers behind the increasing popularity of GLP-1 weight loss medications. Changes in distribution strategies and price adjustments could potentially transform this trend. These factors could democratize access to these treatments.
1 min read
Concerned About Holiday Weight Gain? Prestige Men's Health Offers Affordable, Medically-Supervised Semaglutide Options for Qualifying Individuals
As the holiday season approaches, many individuals express concerns regarding potential weight gain. Prestige Men's Health in Holladay is offering medically supervised weight-loss programs using GLP-1 treatments like semaglutide, providing screening, labs, and continuous monitoring. This comes as more Utah residents seek medical guidance for weight management during this time.
4 min read
Novel GLP-1 Pill Demonstrates Potential for Weight Reduction
Research suggests a daily GLP-1 pill could be a promising option for weight management. The results indicate a potential alternative to injectable weight loss treatments. Health tracking apps like Shotlee can help monitor progress.
1 min read
CEO's Health Journey Inspires Platform Aiding Over 90,000 in Weight Loss
OrderlyMeds, an Atlanta-based telemedicine startup, has garnered over 90,000 customers in under two years, all seeking more effective and personalized weight loss assistance. The company emerged from Founder and CEO Chris Spears' own experience with GLP-1s.
3 min read
Weight Loss Jabs Warning: Risks of Unregulated Semaglutide & GLP-1s
Recent raids on illegal labs highlight the risks of unregulated weight loss medications. Learn how to protect your health and make informed decisions about your weight loss journey. Always consult with a healthcare professional.
4 min read